Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Seizure Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence of Epilepsy and Increase in Accidents and Brain Injuries
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Adverse Effects Associated with the Antiepileptic Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Seizure Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
6.1.2. Market Attractiveness Index, By Seizure Type
6.2. Primary/Generalized Seizures*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Partial/Focal Seizures
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Type*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Vigabatrin
7.2.4. Fenfluramine
7.2.5. Rufinamide
7.2.6. Ganaxolone
7.2.7. Stiripentol
7.2.8. Everolimus
7.2.9. Others
7.3. Electrical Stimulation/Neuromodulation Therapies)
7.3.1. Deep Brain Stimulation (DBS)
7.3.2. Vagus Nerve Stimulation (VNS)
7.3.3. Others
7.4. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals & Specialty Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Sanofi *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. UCB S.A.
11.3. GLENMARK PHARMACEUTICALS LTD.
11.4. Marinus Pharmaceuticals, Inc.
11.5. Biocodex, Inc.
11.6. Teva Pharmaceuticals USA, Inc.
11.7. Novartis AG
11.8. Hikma Pharmaceuticals PLC
11.9. Lupin
11.10. Amneal Pharmaceuticals
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us